KRAS and neoplasm: A cell line from a tumor with a KRAS codon G12V mutation was unresponsive to cetuximab and panitumumab, whereas cell lines from a tumor with a KRAS codon G13D mutation showed an intermediate responsive to cetuximab and panitumumab in comparison with resistant KRAS codon mutation G12V and wild-type cells [70].